<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02926859</url>
  </required_header>
  <id_info>
    <org_study_id>CBD-ESPRIT</org_study_id>
    <nct_id>NCT02926859</nct_id>
  </id_info>
  <brief_title>Enhancing Recovery in Early Schizophrenia</brief_title>
  <official_title>Enhancing Recovery in Early Schizophrenia - a Multi-center, Two-arm, Double-blind, Randomized Phase II Trial Investigating Cannabidiol vs. Placebo as an add-on to an Individualized Antipsychotic Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Institute of Mental Health, Mannheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Institute of Mental Health, Mannheim</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current antipsychotic treatments of schizophrenia are only partially effective, and their use&#xD;
      is often associated with serious side effects. Cannabidiol is a natural counterpart of the&#xD;
      psychoactive component of marijuana, delta-9- tetrahydrocannabinol and has no psychotomimetic&#xD;
      or addictive properties. In a controlled clinical trial of cannabidiol versus amisulpride in&#xD;
      acute paranoid schizophrenia we showed a statistically significant clinical improvement in&#xD;
      all symptoms clusters of schizophrenia compared to baseline with either treatment.&#xD;
      Cannabidiol displayed a significantly superior side-effect profile in particular regarding&#xD;
      prolactin elevation, extrapyramidal symptoms and weight gain. The favorable side-effect&#xD;
      profile and potentially novel mechanism of action identify this molecule as a potential&#xD;
      antipsychotic. However, long-term safety and efficacy data is still lacking. This study is to&#xD;
      evaluate the efficacy and safety of the novel compound cannabidiol in the maintenance&#xD;
      treatment of schizophrenia in comparison to placebo as an add-on to an established treatment&#xD;
      with either amisulpride, aripiprazole, olanzapine, quetiapine or risperidone, in a 12-months,&#xD;
      double-blind, parallel-group, randomized, placebo-controlled clinical trial. Thereby,&#xD;
      relevant data on cannabidiol's antipsychotic potential will be gained.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 8, 2017</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause discontinuation</measure>
    <time_frame>within 12 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in Psychopathology assessed by PANSS</measure>
    <time_frame>6, 9 and 12 month</time_frame>
    <description>Positive and Negative Syndrome Scale (PANSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Psychopathology assessed by CGI</measure>
    <time_frame>6, 9 and 12 month</time_frame>
    <description>Clinical Global Impression (CGI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Psychopathology assessed by BSI-53</measure>
    <time_frame>6, 9 and 12 month</time_frame>
    <description>Brief Symptom Inventory (BSI-53)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Psychopathology assessed by FROGS</measure>
    <time_frame>6, 9 and 12 month</time_frame>
    <description>Functional Remission of General Schizophrenia (FROGS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Depression Scale</measure>
    <time_frame>6, 9 and 12 month</time_frame>
    <description>Calgary Depression Scale for Schizophrenia (CDSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in social and occupational functioning assessed by GAF</measure>
    <time_frame>6, 9 and 12 month</time_frame>
    <description>Global Assessment of Functioning (GAF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in social and occupational functioning assessed by PSP</measure>
    <time_frame>6, 9 and 12 month</time_frame>
    <description>Personal and Social Performance Scale (PSP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in social and occupational functioning assessed by EMA</measure>
    <time_frame>6, 9 and 12 month</time_frame>
    <description>Ecological Momentary Assessment (EMA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Quality of life assessed by WHOQUOL-Bref</measure>
    <time_frame>6, 9 and 12 month</time_frame>
    <description>WHO Quality of Life-Bref (WHOQUOL-Bref)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Quality of life assessed by LQLP</measure>
    <time_frame>6, 9 and 12 month</time_frame>
    <description>Lancashire Quality of Life Profile (LQLP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Neurocognition assessed by B-CATS</measure>
    <time_frame>6, 9 and 12 month</time_frame>
    <description>Brief Cognitive Assessment Tool for Schizophrenia (B-CATS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Neurocognition assessed by BACS</measure>
    <time_frame>6, 9 and 12 month</time_frame>
    <description>Brief Assessment of Cognition in Schizophrenia (BACS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Neurocognition assessed by UPSA-B</measure>
    <time_frame>6, 9 and 12 month</time_frame>
    <description>University of California San Diego Performance based Skills Assessment (UPSA-B)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Neurocognition assessed by MASC</measure>
    <time_frame>6, 9 and 12 month</time_frame>
    <description>Movie for the Assessment of Social Cognition (MASC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Neurocognition assessed by PFA</measure>
    <time_frame>6, 9 and 12 month</time_frame>
    <description>Pictures of Facial Affect (PFA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment adherence</measure>
    <time_frame>6, 9 and 12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Cumulative dose of concomitant or rescue medication</measure>
    <time_frame>6, 9 and 12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Biomarker: alterations of endocannabinoids and lipdomic profiling</measure>
    <time_frame>6, 9 and 12 month</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Side effects: weight gain</measure>
    <time_frame>6, 9 and 12 month</time_frame>
    <description>Body Mass Index, abdominal girth</description>
  </other_outcome>
  <other_outcome>
    <measure>Side effects: Vital Signs</measure>
    <time_frame>6, 9 and 12 month</time_frame>
    <description>heart rate, blood pressure, electrocardiography</description>
  </other_outcome>
  <other_outcome>
    <measure>Side effects: UKU Side Effect rating scale</measure>
    <time_frame>6, 9 and 12 month</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Side effects: Abnormal Involuntary Movement Scale (AIMS)</measure>
    <time_frame>6, 9 and 12 month</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Side effects: Evaluation of extrapyramidal symptoms (EPS)</measure>
    <time_frame>6, 9 and 12 month</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Side effects: physical and neurological examination</measure>
    <time_frame>6, 9 and 12 month</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Standard blood tests</measure>
    <time_frame>6, 9 and 12 month</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Columbia Suicidality Sverity Rating Scale (C-SSRS)</measure>
    <time_frame>6, 9 and 12 month</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Cannabidiol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cannabidiol as add-on to individualized pharmacological treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo as add-on to individualized pharmacological treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabidiol as add-on</intervention_name>
    <description>Cannabidiol capsules 2x200 mg twice a day as add-on to individualized pharmacological treatment with either amisulpride, aripiprazole, olanzapine, quetiapine or risperidone over 26 weeks</description>
    <arm_group_label>Cannabidiol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo as add-on</intervention_name>
    <description>Placebo capsules 2x200 mg twice a day as add-on to individualized pharmacological treatment with either amisulpride, aripiprazole, olanzapine, quetiapine or risperidone over 26 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent given by the subject&#xD;
&#xD;
          -  DSM-IV-TR diagnosis of schizophrenic psychosis (295.10-30, 295.90)&#xD;
&#xD;
          -  First documented diagnosis of schizophrenia must not be no older than seven years.&#xD;
&#xD;
          -  Patients must receive a stable dose of amisulpride, aripiprazole, olanzapine,&#xD;
             quetiapine or risperidone (TAU: treatment as usual) at least 4 weeks prior to&#xD;
             inclusion in the study to ensure that the maximal effect of the previous medication&#xD;
             has been received.&#xD;
&#xD;
          -  Initial PANSS total score of ≤ 75 at baseline.&#xD;
&#xD;
          -  proper contraception in female patients of childbearing potential&#xD;
&#xD;
          -  body mass index between 18 and 40.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lack of accountability&#xD;
&#xD;
          -  positive urine drug-screening for illicit drugs at screening (except cannabinoids and&#xD;
             benzodiazepines)&#xD;
&#xD;
          -  serious suicidal risk at screening visit&#xD;
&#xD;
          -  other relevant interferences of axis 1 according to diagnostic evaluation (MINI)&#xD;
             including residual forms of schizophrenia.&#xD;
&#xD;
          -  other relevant neurological or other medical disorders&#xD;
&#xD;
          -  pregnancy or lactation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>F. Markus Leweke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Institute of Mental Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dep. of Psychiatry and Psychotherapy, Central Institute of Mental Health</name>
      <address>
        <city>Mannheim</city>
        <state>BW</state>
        <zip>68159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Psychiatry and Psychotherapy, Ludwig-Maximillians-University Munich</name>
      <address>
        <city>Munich</city>
        <state>BY</state>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Psychiatry and Psychotherapy, Charité, Campus Charité-Mitte</name>
      <address>
        <city>Berlin</city>
        <state>B</state>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Psychiatry, Psychotherapy, and Psychosomatics, RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <state>NRW</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Psychiatry and Psychotherapy, University Hospital of Cologne</name>
      <address>
        <city>Cologne</city>
        <state>NRW</state>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Psychiatry und Psychotherapy, University Hospital Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 7, 2016</study_first_submitted>
  <study_first_submitted_qc>October 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2016</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cannabidiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

